Chemomab Therapeutics (CMMB) Accounts Payables (2017 - 2025)
Chemomab Therapeutics (CMMB) posted Accounts Payables of $485000.0 for Q4 2025, up 150.0% on a QoQ basis from $194000.0 in Q3 2025, and down 23.38% year-over-year from $633000.0 in Q4 2024.
Chemomab Therapeutics (CMMB) Accounts Payables (2017 - 2025) Analysis & Trends
Chemomab Therapeutics' Accounts Payables history runs 9 years deep, the most recent figure standing at $485000.0 for Q4 2025.
- Quarterly Accounts Payables fell 23.38% year-over-year to $485000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $485000.0 (down 23.38% YoY) and the FY2025 annual result came in at $485000.0, down 23.38% from the prior year.
- Accounts Payables was $485000.0 for Q4 2025 at Chemomab Therapeutics, up from $194000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $2.3 million in Q2 2023 and bottomed at $194000.0 in Q3 2025.
- A 5-year average of $1.0 million and a median of $682000.0 in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2021 — Accounts Payables surged 1336.56% — and 2024, when it slumped 76.23%.
- Chemomab Therapeutics' Accounts Payables stood at $1.3 million in 2021, then rose by 26.35% to $1.7 million in 2022, then tumbled by 69.43% to $516000.0 in 2023, then grew by 22.67% to $633000.0 in 2024, then dropped by 23.38% to $485000.0 in 2025.
- Business Quant data shows CMMB's Accounts Payables at $485000.0 in Q4 2025, $194000.0 in Q3 2025, and $378000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - | 10.62 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 8.64 Mn |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn | 423.55 Mn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Chemomab Therapeutics | 714.32 Mn | 703.95 Mn | - | 485,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 485,000.00 |
| Sep 30, 2025 | 194,000.00 |
| Jun 30, 2025 | 378,000.00 |
| Mar 31, 2025 | 490,000.00 |
| Dec 31, 2024 | 633,000.00 |
| Sep 30, 2024 | 386,000.00 |
| Jun 30, 2024 | 1.11 Mn |
| Mar 31, 2024 | 527,000.00 |
| Dec 31, 2023 | 516,000.00 |
| Sep 30, 2023 | 731,000.00 |
| Jun 30, 2023 | 2.35 Mn |
| Mar 31, 2023 | 2.22 Mn |
| Dec 31, 2022 | 1.69 Mn |
| Sep 30, 2022 | 1.25 Mn |
| Jun 30, 2022 | 1.43 Mn |
| Mar 31, 2022 | 1.49 Mn |
| Dec 31, 2021 | 1.34 Mn |
| Sep 30, 2021 | 481,000.00 |
| Jun 30, 2021 | 472,000.00 |
| Mar 31, 2021 | 2.08 Mn |